New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2014
08:36 EDTTNXPTonix Pharmaceuticals raises $7.8M in a registered direct offering
Tonix announced it has agreed to sell 657,000 shares of common stock in a registered direct offering at a price of $11.90 per share for aggregate gross proceeds of approximately $7.8M. Tonix expects to use the net proceeds of the offering to support the continued development of TNX-102 SL for the treatment of fibromyalgia, to initiate clinical trials of TNX-102 SL for the treatment of post-traumatic stress disorder, to initiate clinical trials of TNX-201 for episodic tension-type headache, and further develop our other pipeline programs, and for working capital and other general corporate purposes, and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated. Roth Capital Partners acted as the exclusive placement agent for the offering.
News For TNXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
15:50 EDTTNXPTonix Pharmaceuticals announces two abstracts accepted for presentation at EULAR
Tonix Pharmaceuticals announced that two abstracts have been accepted for presentation at the European League Against Rheumatism Annual Congress, EULAR 2015, in Rome, Italy. The two accepted abstracts are: "TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement" and "TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization."
May 20, 2015
09:42 EDTTNXPTonix Pharmaceuticals management to meet with Roth Capital
Meeting to be held in Boston on May 27 hosted by Roth Capital.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use